Gilead and Xilio Therapeutics Join Forces to Develop XTX301 for the Treatment of Cancers
Shots:
- Gilead and Xilio have entered into an agreement under which Gilead received an exclusive global license to develop and commercialize Xilio's XTX301, currently under P-I assessment
- Under the collaboration, Xilio will obtain $43.5M upfront incl. $30M in cash & $13.5M in equity, additional $604M comprising of equity investments, a transition fee as well as specified development, regulatory & sales-based milestones plus high single digits to mid-teens global net-sales-based tiered royalties
- Xilio will conduct XTX301’s P-I study and after the clinical data delivery, Gilead can take over its development for a $75M transition fee. Xilio will receive ~$29M in equity investments & milestones before transition
Ref: Gilead | Image: Gilead
Related News:- Merck Signs a Clinical Trial Collaboration with Xilio for Anti-CTLA-4 Monoclonal Antibody Program
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
